An Open-label Safety and Tolerability Study of LTS 0.3% With Red Light Applied to the Backs of Healthy Volunteers
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Lemuteporfin (Primary)
- Indications Acne vulgaris; Benign prostatic hyperplasia; Male pattern baldness
- Focus Adverse reactions
- 22 Aug 2013 New trial record
- 24 Jul 2013 Status changed from recruiting to completed according to ClinicalTrials.gov.